The Study of IL-20 in Cancer-Induced Osteolysis

• Main Authors: Cheng-YingWu, 吳承穎
• Other Authors: Ming-Shi Chang
• Format: Others
• Language: zh-TW
• Published: 2014
• Online Access: http://ndltd.ncl.edu.tw/handle/9cf4x6

碩士 === 國立成功大學 === 生物化學暨分子生物學研究所 === 102 === Cancer is the most common disease in the world. It may also spread to distant parts of the body and increase the mortality. Bone is one of the site for cancer metastasis. Cancer cells in the bone reduce bone mineral density and induce pain in patients. IL-20 is a cytokine belonging to the IL-10 family. IL-20 binds to a heterodimer receptor complex IL-20R1/IL-20R2 mediating its signal transduction. Previous studies showed that IL-20 is involved in several diseases, such as psoriasis, rheumatoid arthritis and cancer. In our previous study, anti-IL-20 monoclonal antibody 7E suppressed breast cancer-induced osteolysis. To investigate whether 7E can suppress other cancer cells-induced osteolysis, we used five different kinds of cancers: prostate cancer, esophageal cancer, oral cancer, osteosarcoma and multiple myeloma to establish cancer-induced osteolysis animal models. Our result showed that 7E suppressed prostate cancer and esophageal cancer induced osteolysis. However, 7E did not suppress osteolysis in oral cancer, osteosarcoma and multiple myeloma. Furthermore, IL-20 increased gene expression of sRANKL, cathepsin G and cathepsin K and sRANKL protein expression in prostate cancer cell. Condition medium of prostate cancer cell suppressed pre-osteoblast proliferation. 7E also suppressed prostate cancer cell proliferation, migration and colony formation. IL-20 also induced phosphorylation of P-38, Erk1/2, Akt and NFκB in prostate cancer cell. In addition, IL-20 upregulated STAT3, vimentin, fibronectin and N-cadherin gene expression. 7E also suppressed esophageal cancer cell proliferation, migration and colony formation. Our study provides the evidence that 7E has a protective function in prostate and esophageal cancer-induced osteolysis in animal model and anti-IL-20 monoclonal antibody 7E may have therapeutic potential in cancer-induced osteolysis.